The second annual survey shows pharma is making progress, but still has a long way to go to digitally enable the marketing function.
Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma workplaces shows.
It’s more than just drugmakers’ exorbitant prices. Experts say hospitals and patients both play a role.
This marks the fourth acquisition for Relevate, which plans to leverage games to round out its omnichannel life sciences offering.
The $2,000 out-of-pocket cap, despite being overshadowed by the IRA’s provision allowing Medicare price negotiation, has drawn scrutiny of its own.
There’s a nettlesome gap between big-picture commercial strategy and front-line sales. Marketers say it’s not likely to be bridged anytime soon.
Here’s why silver-haired Internet celebs might soon be making rounds on the Alzheimer’s drug marketing scene.
Pfizer received upbeat news for its gene therapies in hemophilia A and B last week, but lingering doubts cloud their commercial future.
In the final part of MM+M’s three-part series, we assess the likelihood that the industry will embrace the new rules — and the benefits that could accrue from doing so.
In the second part of MM+M’s three-part series, we address the practical effects of the new guidance — and its likely effect on influencer marketing.
Get the most out of
Register for free and enjoy unlimited access to: